Study finds that people with higher levels of depressive symptoms are more susceptible to the emotional influence of negative surrounding images, perceiving even neutral content as more emotionally negative when it's paired with negative peripheral information. This effect was not mitigated by positive imagery, highlighting an asymmetry in how depression affects emotional processing. The findings underscore the importance of contextual cues in shaping emotional experiences in individuals with depression and point to potential strategies for therapeutic interventions that address these contextual sensitivities. 

Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announced the recent release of its Nach01 foundation model on Amazon Web Services (AWS), available via AWS Marketplace, a curated storefront helping companies of all sizes find, buy, and deploy solutions from AWS Partners. The launch represents a major step in the ongoing collaboration between AWS and Insilico Medicine’s Pharma.AI Platform, aimed at providing access to advanced AI tools for drug design. Nach01 leverages a large language model to process both structural and spatial data. Combining strengths from both predecessors, Nach01 is designed to solve hundreds of diverse tasks, providing a broad and comprehensive range of chemical knowledge.

“Lifestyle Interventions for Treatment and Remission of Type 2 Diabetes and Prediabetes in Adults,” offers a comprehensive and evidence-based roadmap for clinicians to effectively incorporate therapeutic lifestyle behavior interventions as a mainstay of treatment, while also complementing existing guidelines for diabetes, many of which mention lifestyle as part of care but often do not provide specifics.

The Lieber Institute for Brain Development (LIBD) is revolutionizing its drug discovery efforts by expanding its technology capabilities on Amazon Web Services (AWS); migrating its IT infrastructure to fully utilize AWS gen AI and compute services to advance research. The Lieber Institute, home to the world’s largest collection of donated brains used for mental illness research, and a recipient of the 2024 Amazon Web Services (AWS) IMAGINE Grant, plans to develop a new tool called GRAPE that combines generative and predictive AI to find new, more effective treatments for brain disorders such as schizophrenia.

People with COVID-like symptoms returned to optimal physical well-being an average of three months after infection, but took up to nine months to return to top mental well-being.  One year after infection about 20% of study participants continued to experience overall suboptimal health-related quality of life.